Ardent Health, Inc. (ARDT)
| Market Cap | 1.36B -35.8% |
| Revenue (ttm) | 6.43B +6.7% |
| Net Income | 134.28M -40.2% |
| EPS | 0.95 -42.0% |
| Shares Out | 143.35M |
| PE Ratio | 9.93 |
| Forward PE | 7.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,728 |
| Open | 9.69 |
| Previous Close | 9.67 |
| Day's Range | 9.38 - 9.70 |
| 52-Week Range | 7.71 - 15.48 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 12.41 (+30.77%) |
| Earnings Date | May 5, 2026 |
About ARDT
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free... [Read more]
Financial Performance
In 2025, Ardent Health's revenue was $6.32 billion, an increase of 6.01% compared to the previous year's $5.97 billion. Earnings were $135.81 million, a decrease of -35.43%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ARDT stock is "Buy." The 12-month stock price target is $12.41, which is an increase of 30.77% from the latest price.
News
Ardent Health Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
A proactive leadership transition aims to drive operational rigor and margin expansion, supported by the IMPACT Program targeting $55 million in savings. Despite industry-wide volume softness and reimbursement headwinds, the organization is investing in ambulatory growth, AI initiatives, and disciplined M&A, while maintaining a strong financial outlook.
Ardent Health price target lowered to $9 from $10 at BofA
BofA lowered the firm’s price target on Ardent Health (ARDT) to $9 from $10 and keeps an Underperform rating on the shares. The firm is lowering its price targets for…
Ardent Health to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participat...
Morgan Stanley says Ardent softer volume commentary adds to list of concerns
Morgan Stanley notes after Ardent Health (ARDT) announced the appointment of COO Dave Caspers as President and CEO, effective immediately, that the CFO and investor relations team commented that the…
Ardent Health names Dave Caspers as CEO
Ardent Health (ARDT) announced that Dave Caspers has been appointed President and Chief Executive Officer, effective immediately. Mr. Caspers, who previously served as Chief Operating Officer, succeed...
Ardent Health Appoints Dave Caspers as CEO
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announc...
Ardent Health Transcript: AGM 2026
The meeting established a quorum and proceeded with the election of eleven directors, approval of executive compensation, and ratification of the independent auditor, with all proposals passing by majority or plurality vote.
Ardent Health partners with Fujifilm to deliver Synapse imaging solutions
Ardent Health (ARDT) has partnered with Fujifilm Healthcare Americas Corporation to implement its Synapse enterprise imaging solutions across Ardent’s acute care hospital footprint across six states. ...
Ardent Health and Fujifilm Partner to Deliver Synapse Enterprise Imaging Across Radiology and Cardiology Throughout All Facilities
BRENTWOOD, Tenn. & LEXINGTON, Mass.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., has partnered with FUJIFILM H...
Ardent Health Transcript: Bank of America Global Healthcare Conference 2026
Leaders outlined a three-part growth strategy focused on margin improvement, regional and outpatient expansion, and selective M&A. Q1 saw solid adjusted admissions growth, strong outpatient performance, and stabilized denial rates. The IMPACT program and AI initiatives are driving margin gains, with a mid-teens EBITDA margin targeted over the next few years.
Ardent Health price target raised to $13.50 from $13 at UBS
UBS raised the firm’s price target on Ardent Health (ARDT) to $13.50 from $13 and keeps a Buy rating on the shares.
Ardent Health Earnings Call Transcript: Q1 2026
Revenue rose 7% and Adjusted EBITDA grew 26% year-over-year, driven by cost discipline, outpatient growth, and IMPACT Program savings. Guidance for 2026 is reaffirmed, with continued focus on margin expansion, ambulatory investment, and operational efficiency.
Ardent Health Earnings release: Q1 2026
Ardent Health released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Ardent Health Slides: Q1 2026
Ardent Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Ardent Health Quarterly report: Q1 2026
Ardent Health has published its Q1 2026 quarterly earnings report on May 6, 2026.
Ardent Health Reports First Quarter 2026 Results
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health, Inc. (NYSE: ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today a...
Ardent Health to Participate in the Bank of America 2026 Healthcare Conference
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that the Company will participat...
Ardent Health Announces First Quarter 2026 Results Conference Call and Webcast Date
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its first qua...
Ardent Health price target lowered to $13 from $15 at Guggenheim
Guggenheim lowered the firm’s price target on Ardent Health (ARDT) to $13 from $15 and keeps a Buy rating on the shares.
Ardent Health Proxy statement: Proxy filing
Ardent Health filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Ardent Health Proxy statement: Proxy filing
Ardent Health filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Ardent Health Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Strong 2025 growth was driven by admissions and outpatient expansion, but payer denials and professional fee inflation remain key headwinds for 2026. AI and operational initiatives are improving efficiency, while joint ventures and ambulatory investments support long-term growth. Margin pressures from exchange subsidy loss and payer dynamics are closely monitored.
Ardent Health Transcript: Leerink Global Healthcare Conference 2026
Investments in AI and digital platforms are driving operational transformation, with early productivity gains and plans for broader rollout. Financial headwinds from subsidy expirations and payer denials are being managed through cautious assumptions and technology-driven improvements. Outpatient and ASC expansion, joint ventures, and workforce initiatives are key growth drivers.
Ardent Health price target lowered to $15 from $16 at Leerink
Leerink lowered the firm’s price target on Ardent Health (ARDT) to $15 from $16 and keeps an Outperform rating on the shares. The firm says the company’s Q4 results were…
Ardent Health price target lowered to $13 from $14 at UBS
UBS analyst AJ Rice lowered the firm’s price target on Ardent Health (ARDT) to $13 from $14 and keeps a Buy rating on the shares.